JP2022535735A5 - - Google Patents

Info

Publication number
JP2022535735A5
JP2022535735A5 JP2021570299A JP2021570299A JP2022535735A5 JP 2022535735 A5 JP2022535735 A5 JP 2022535735A5 JP 2021570299 A JP2021570299 A JP 2021570299A JP 2021570299 A JP2021570299 A JP 2021570299A JP 2022535735 A5 JP2022535735 A5 JP 2022535735A5
Authority
JP
Japan
Prior art keywords
aso
cpsgps
cps
sequence
lngpslnapslntpslnapslnapsapsaps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021570299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535735A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035212 external-priority patent/WO2020243490A2/en
Publication of JP2022535735A publication Critical patent/JP2022535735A/ja
Publication of JP2022535735A5 publication Critical patent/JP2022535735A5/ja
Pending legal-status Critical Current

Links

JP2021570299A 2019-05-31 2020-05-29 修飾ギャップマーオリゴヌクレオチドおよび使用方法 Pending JP2022535735A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962855793P 2019-05-31 2019-05-31
US62/855,793 2019-05-31
US201962937760P 2019-11-19 2019-11-19
US62/937,760 2019-11-19
US201962943532P 2019-12-04 2019-12-04
US62/943,532 2019-12-04
PCT/US2020/035212 WO2020243490A2 (en) 2019-05-31 2020-05-29 Modified gapmer oligonucleotides and methods of use

Publications (2)

Publication Number Publication Date
JP2022535735A JP2022535735A (ja) 2022-08-10
JP2022535735A5 true JP2022535735A5 (cg-RX-API-DMAC7.html) 2023-05-31

Family

ID=72179172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570299A Pending JP2022535735A (ja) 2019-05-31 2020-05-29 修飾ギャップマーオリゴヌクレオチドおよび使用方法

Country Status (15)

Country Link
US (1) US11466274B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976056A2 (cg-RX-API-DMAC7.html)
JP (1) JP2022535735A (cg-RX-API-DMAC7.html)
KR (1) KR20220024192A (cg-RX-API-DMAC7.html)
CN (1) CN113905744A (cg-RX-API-DMAC7.html)
AU (1) AU2020282828A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023488A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141874A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021018034A2 (cg-RX-API-DMAC7.html)
IL (1) IL288259A (cg-RX-API-DMAC7.html)
MX (1) MX2021014206A (cg-RX-API-DMAC7.html)
PE (1) PE20220574A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112741XA (cg-RX-API-DMAC7.html)
TW (1) TW202113079A (cg-RX-API-DMAC7.html)
WO (1) WO2020243490A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021119325A1 (en) * 2019-12-12 2021-06-17 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CA3187388A1 (en) * 2020-07-27 2022-02-03 Jin Hong Hbv binding oligonucleotides and methods of use
CN117500924A (zh) * 2020-12-31 2024-02-02 赛卡纳制药股份两合公司 用于降低血管紧张素转换酶2(ace2)表达的寡核苷酸及其在治疗病毒感染中的用途
US20250243491A1 (en) 2021-09-01 2025-07-31 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
CA3230382A1 (en) 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
KR20240131441A (ko) 2022-01-10 2024-08-30 오스퍼바이오 테라퓨틱스 인크. B형 간염 바이러스(hbv) 발현의 조절
JP2025509552A (ja) * 2022-03-17 2025-04-11 アリゴス セラピューティクス,インコーポレーテッド 修飾ギャップマーオリゴマー及びその使用方法
WO2024182446A2 (en) 2023-02-28 2024-09-06 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
US20240352464A1 (en) 2023-03-07 2024-10-24 Aligos Therapeutics, Inc. Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
EP4600358A4 (en) * 2023-04-14 2026-05-20 Rigerna Therapeutics Suzhou Co Ltd COMPOUND TO INHIBIT C3 GENE EXPRESSION, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USES
US20250368996A1 (en) 2024-05-14 2025-12-04 Aligos Therapeutics, Inc. Modified antisense oligonucleotides for treating hepatitis b virus
CN120796266A (zh) * 2024-07-08 2025-10-17 北京悦康科创医药科技股份有限公司 一种降低hbv基因表达的反义寡核苷酸及其应用
WO2026124677A1 (zh) * 2024-12-13 2026-06-18 成都先衍生物技术有限公司 一种4'-螺环修饰的苏糖核苷亚磷酰胺化合物及其在寡核苷酸中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127446A1 (en) 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
EP2284269B1 (en) 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
ES2651308T3 (es) * 2009-10-16 2018-01-25 Glaxo Group Limited Inhibidores antisentido de HBV
AU2010312751B2 (en) 2009-10-29 2014-07-24 Osaka University Bridged artificial nucleoside and nucleotide
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
SI3505528T1 (sl) 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
EP3336189A1 (en) 2012-04-20 2018-06-20 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
CN104684857B (zh) 2012-09-11 2018-10-12 3M创新有限公司 具有分区的结构的玻璃粒料
EP2899197B1 (en) 2012-09-21 2017-03-22 Osaka University Oligonucleotide and artificial nucleoside having guanidine bridge
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
US9943604B2 (en) 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
US10358643B2 (en) 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
EP3109254B1 (en) 2014-02-18 2018-04-11 Osaka University Crosslinked nucleoside and nucleotide
GB201408623D0 (en) * 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
AU2015329974B2 (en) 2014-10-10 2019-06-20 F. Hoffmann-La Roche Ag GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
EP3221329A1 (en) 2014-11-19 2017-09-27 Roche Innovation Center Copenhagen A/S Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages
EP3353305A4 (en) 2015-09-25 2019-09-18 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
AU2017285350A1 (en) * 2016-06-17 2018-12-20 F. Hoffmann-La Roche Ag Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
US11286275B2 (en) 2017-02-21 2022-03-29 Osaka University Nucleic acid compound and oligonucleotide
US11261440B2 (en) 2017-02-21 2022-03-01 Osaka University Antisense oligonucleic acid
KR20200030594A (ko) * 2017-10-16 2020-03-20 에프. 호프만-라 로슈 아게 B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
US20200147124A1 (en) 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
KR20210126636A (ko) 2019-02-14 2021-10-20 알리고스 테라퓨틱스 인코포레이티드 이환식 설폰아마이드

Similar Documents

Publication Publication Date Title
ES2242291T3 (es) Nucleotidos bi y triciclicos, analogos de nucleotidos y oligonucleotidos.
KR102500675B1 (ko) B형 간염 바이러스 감염에 대한 RNAi 작용제
EP2334692B1 (en) Rna monomers containing o-acetal levulinyl ester groups and their use in rna microarrays
JP2022551124A5 (cg-RX-API-DMAC7.html)
JP2023515664A5 (cg-RX-API-DMAC7.html)
JP4791043B2 (ja) 同一固体支持体上で、2以上のオリゴヌクレオチドをタンデムに合成するための方法および組成物
PE20220574A1 (es) Oligonucleotidos gapmer modificados y metodos de uso
JP2005533517A5 (cg-RX-API-DMAC7.html)
RU2020115761A (ru) МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В
HUT76094A (en) Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US7034133B2 (en) Oligonucleotide analogues
KR102533038B1 (ko) 변형된 올리고뉴클레오티드 및 사용 방법
JP2021523720A5 (cg-RX-API-DMAC7.html)
CN101784556A (zh) 用于rna合成的硫代碳保护基团
EP1007655A1 (en) Rnase l activators and antisense oligonucleotides effective to treat rsv infections
JPH09511250A (ja) 核酸治療に有用な修飾オリゴヌクレオチド及び中間体
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
JP2021505129A5 (cg-RX-API-DMAC7.html)
JP2019529406A5 (cg-RX-API-DMAC7.html)
RU2020135289A (ru) Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в
Adah et al. Chemistry and biochemistry of 2', 5'-oligoadenylate-based antisense strategy
JP2024073525A5 (cg-RX-API-DMAC7.html)
JP2020521491A5 (cg-RX-API-DMAC7.html)
WO1996003500A1 (en) Sustance with antiviral activity
JP2025509552A5 (cg-RX-API-DMAC7.html)